* Newstin.co.uk is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.co.uk and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.co.uk is for sale! *
Full Coverage

Lundbeck acquires European commercialization rights for Flurizan® from Myriad, USA - a new drug in..

                   
euroinvestor.co.uk
22-May-2008
        
Story Timeline:  143 days

H. Lundbeck A/S and Myriad Genetics, Inc. today announced that Lundbeck has acquired European commercialization rights to Myriad's Flurizan® (tarenflurbil). Flurizan® might have the potential to delay disability in patients suffering from Alzheimer's disease. Myriad and Lundbeck have entered into... [read full story]                    

Add Comment
Latest article on this story:

Myriad Making Good Deals (at Motley Fool)

 yahoo.com 23-May-2008
First article on this story:

Myriad Genetics Selects Lundbeck as European Partner for Flurizan

 tmcnet.com 22-May-2008
Selected publications with coverage of this story:
ibtimes.com redorbit.com marketwire.com marketwatch.com yahoo.com earthtimes.org euroinvestor.co.uk ad-hoc-news.de pharmiweb.co.uk tmcnet.com finanznachrichten.de
RELATED
Found 4 documents:

Myriad Genetics to partner with H. Lundbeck on Flurizan

pharmiweb.co.uk
22-May-2008
        

LONDON (MarketWatch) -- Myriad Genetics said it will get $100 million upfront and up to $250 million from regulatory approvals from H. Lundbeck A/S in return for European commercialization rights to Alzheimer's disease drug candiate Flurizan. Myriad also will get escalating royalties of 20% to...

                   
earthtimes.org: SALT LAKE CITY, UT -- 05/22/08 -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) today announced the selection of H. Lundbeck A/S for European commercialization of Flurizan®, Myriad's lead therapeutic.. earthtimes.org

Myriad Genetics Selects Lundbeck as European Partner for Flurizan

earthtimes.org
22-May-2008
        

SALT LAKE CITY, UT -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the selection of H. Lundbeck A/S for European commercialization of Flurizan®, Myriad's lead therapeutic candidate for the treatment of Alzheimer's disease. Myriad and Lundbeck have entered into a European commercialization...

Lundbeck buys rights for Alzheimer's treatment

finanznachrichten.de
22-May-2008
        

COPENHAGEN (Thomson Financial) - Lundbeck AS said it has acquired the European commercialisation rights for Flurizan, a phase III drug candidate that may have the potential to treat Alzheimer's disease, from United States-based Myriad Genetics Inc. The Danish pharmaceutical company said it has...

                   

Lundbeck acquires European commercialization rights for Flurizan® from Myriad, USA - a new drug...

ad-hoc-news.de
22-May-2008
        

H. Lundbeck A/S and Myriad Genetics, Inc. today announced that Lundbeck has acquired European commercialization rights to Myriad's Flurizan® (tarenflurbil). Flurizan® might have the potential to delay disability in patients suffering from Alzheimer's dise